PYC announced on 17th August that dosing had been completed for Cohort #1.
My understanding is that PYC then accumulates data for the ensuing 4 weeks and submits this data for review, and if all is well, for the Safety Committee to provide approval to start clinical dosing for Cohort #2, (medium dose).
Next Thursday, 14th September, marks four weeks since that announcement on 17th August.
I believe that as we progress to Cohort #2, medium dose, we will be getting into a dosage metric that more likely carries the possibility of VP - 001 to demonstrate its potential to provide measurable eyesight improvements for patients, (over time). This comment is not meant to underscore the safety profile of VP - 001, as patient safety needs to be an absolute priority, however with Cohort #2 we are also moving into a space that may further validate our safety profile PLUS quite a bit more.
- Forums
- ASX - By Stock
- PYC
- Safety approval VP-001
Safety approval VP-001
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PYC (ASX) to my watchlist
|
|||||
Last
12.0¢ |
Change
-0.005(4.00%) |
Mkt cap ! $559.9M |
Open | High | Low | Value | Volume |
12.5¢ | 13.3¢ | 12.0¢ | $624.5K | 5.016M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 1227634 | 12.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.5¢ | 130000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 1227634 | 0.120 |
13 | 1531061 | 0.115 |
11 | 503370 | 0.110 |
11 | 1225445 | 0.105 |
23 | 1558294 | 0.100 |
Price($) | Vol. | No. |
---|---|---|
0.125 | 130000 | 2 |
0.130 | 429500 | 3 |
0.135 | 547949 | 8 |
0.140 | 1503540 | 5 |
0.145 | 255000 | 2 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |